Wolverine Trading’s Akero Therapeutics AKRO Stock Holding History

Wolverine Trading’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$241K	Buy	+5,059	New	+$245K	﹤0.01%	4691
2025 Q2	–	Sell	-14,296	Closed	-$611K	–	4589
2025 Q1	$611K	Buy	+14,296	New	+$606K	﹤0.01%	2751
2023 Q4	–	Sell	-4,871	Closed	-$96.1K	–	4439
2023 Q3	$246K	Buy	+4,871	New	+$227K	﹤0.01%	3525
2023 Q2	–	Sell	-6,488	Closed	-$297K	–	4186
2023 Q1	$245K	Buy	6,488 +136	+2%	+$6.06K	﹤0.01%	3221
2022 Q4	$348K	Buy	+6,352	New	+$272K	﹤0.01%	2641

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wolverine Trading's AKRO Position: Q3 2025 in Review

Wolverine Trading opened a new position in Akero Therapeutics (AKRO) in Q3 2025: 5,059 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #4691 among its holdings. This is a return to the name: Wolverine Trading previously reported a position in AKRO as recently as Q1 2025.

Wolverine Trading first reported a position in AKRO in Q4 2022 and has held it in 5 quarters since. The position peaked at $611K in Q1 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

Wolverine Trading held 5,059 shares of Akero Therapeutics worth $241K as of Q3 2025.
Akero Therapeutics was a new Wolverine Trading position in Q3 2025.
Akero Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4691 holding.
Wolverine Trading first reported a position in Akero Therapeutics in Q4 2022 and has held it in 5 quarters since.
Wolverine Trading's Akero Therapeutics position peaked at $611K in Q1 2025.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.